PL3313865T3 - Syntetyczne związki peptydowe i sposoby zastosowania - Google Patents
Syntetyczne związki peptydowe i sposoby zastosowaniaInfo
- Publication number
- PL3313865T3 PL3313865T3 PL16815455T PL16815455T PL3313865T3 PL 3313865 T3 PL3313865 T3 PL 3313865T3 PL 16815455 T PL16815455 T PL 16815455T PL 16815455 T PL16815455 T PL 16815455T PL 3313865 T3 PL3313865 T3 PL 3313865T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- synthetic peptide
- peptide compounds
- compounds
- synthetic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/12011—Astroviridae
- C12N2770/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185202P | 2015-06-26 | 2015-06-26 | |
| PCT/US2016/039421 WO2016210370A2 (en) | 2015-06-26 | 2016-06-24 | Synthetic peptide compounds and methods of use |
| EP16815455.7A EP3313865B1 (en) | 2015-06-26 | 2016-06-24 | Synthetic peptide compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3313865T3 true PL3313865T3 (pl) | 2021-10-25 |
Family
ID=57586008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16815455T PL3313865T3 (pl) | 2015-06-26 | 2016-06-24 | Syntetyczne związki peptydowe i sposoby zastosowania |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10933116B2 (pl) |
| EP (1) | EP3313865B1 (pl) |
| JP (2) | JP6820917B2 (pl) |
| ES (1) | ES2875498T3 (pl) |
| PL (1) | PL3313865T3 (pl) |
| WO (1) | WO2016210370A2 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10947279B2 (en) | 2015-06-26 | 2021-03-16 | Realta Holdings, Llc | Synthetic peptide compounds and methods of use |
| ES2996888T3 (en) * | 2018-01-09 | 2025-02-13 | Realta Holdings Llc | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
| WO2020168036A1 (en) * | 2019-02-15 | 2020-08-20 | Eastern Virginia Medical School | Pic1 variants with improved solubility and methods of using the same |
| EP4222168A4 (en) * | 2020-09-30 | 2024-09-04 | Realta Life Sciences, Inc. | PEPTIDES AND METHODS OF USE |
| CA3194446A1 (en) * | 2020-11-02 | 2022-05-05 | Neel K. Krishna | Peptides and methods of use |
| KR20230093330A (ko) * | 2020-11-02 | 2023-06-27 | 리얼타 라이프 사이언시즈, 인크. | 펩티드 및 사용 방법 |
| EP4240392A4 (en) * | 2020-11-09 | 2024-10-09 | Realta Life Sciences, Inc. | PEPTIDE FORMULATIONS AND METHODS OF USE |
| WO2022191193A1 (ja) * | 2021-03-12 | 2022-09-15 | 国立大学法人 新潟大学 | 溶血反応により誘発される腎障害の抑制 |
| US20230404958A1 (en) * | 2021-03-12 | 2023-12-21 | Niigata University | Agent for inhibiting renal damage induced by rhabdomyolysis |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625049A (en) | 1993-05-12 | 1997-04-29 | Us Health | Nucleic acids encoding human astrovirus serotype 2 |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| WO1999044625A1 (en) | 1998-03-03 | 1999-09-10 | John Hopkins University | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
| WO2000043027A1 (en) | 1999-01-19 | 2000-07-27 | University Of Louisville Research Foundation, Inc. | Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease |
| US6696562B1 (en) | 2000-07-10 | 2004-02-24 | The United States Of America As Represented By The Secretary Of Agriculture | Avian astrovirus |
| US7638481B2 (en) | 2003-09-05 | 2009-12-29 | University Of Louisville Research Foundation, Inc. | Treatment of spinal cord injury |
| US20070116672A1 (en) | 2003-09-05 | 2007-05-24 | Kotwal Girish J | Treatment of rheumatic diseases |
| US20070012617A1 (en) | 2003-09-05 | 2007-01-18 | Sadakatsu Suzuki | Method for producing micro-porous film of thermoplastic resin |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| US7381524B2 (en) | 2003-10-10 | 2008-06-03 | Wisconsin Alumni Research Foundation | Method to detect antibodies specific for type-2 turkey astrovirus |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8241843B2 (en) | 2006-06-15 | 2012-08-14 | Eastern Virginia Medical School | Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof |
| AU2008239595A1 (en) | 2007-04-11 | 2008-10-23 | Pestka Biomedical Laboratories, Inc. | Interferons of Rhesus and Cynomolgus origin and uses thereof |
| US10172950B2 (en) * | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| US20130183662A1 (en) | 2010-04-22 | 2013-07-18 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
| EP2606058B1 (en) | 2010-07-21 | 2017-03-08 | Eastern Virginia Medical School | Peptide compounds to regulate the complement system |
| US10005818B2 (en) | 2010-07-21 | 2018-06-26 | Realta Holdings, Llc | Derivative peptide compounds and methods of use |
| WO2013138730A1 (en) | 2012-03-16 | 2013-09-19 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of c1-inhibitors |
-
2016
- 2016-06-24 ES ES16815455T patent/ES2875498T3/es active Active
- 2016-06-24 JP JP2018519267A patent/JP6820917B2/ja active Active
- 2016-06-24 US US15/738,786 patent/US10933116B2/en active Active
- 2016-06-24 WO PCT/US2016/039421 patent/WO2016210370A2/en not_active Ceased
- 2016-06-24 PL PL16815455T patent/PL3313865T3/pl unknown
- 2016-06-24 EP EP16815455.7A patent/EP3313865B1/en active Active
-
2021
- 2021-01-05 JP JP2021000312A patent/JP6992201B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6820917B2 (ja) | 2021-01-27 |
| US10933116B2 (en) | 2021-03-02 |
| JP6992201B2 (ja) | 2022-02-03 |
| US20200254053A1 (en) | 2020-08-13 |
| EP3313865A4 (en) | 2019-05-15 |
| EP3313865B1 (en) | 2021-04-07 |
| CA2987141A1 (en) | 2016-12-29 |
| JP2021063106A (ja) | 2021-04-22 |
| WO2016210370A3 (en) | 2017-02-23 |
| JP2018524402A (ja) | 2018-08-30 |
| ES2875498T3 (es) | 2021-11-10 |
| EP3313865A2 (en) | 2018-05-02 |
| WO2016210370A2 (en) | 2016-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286316A (en) | New micro-dystrophins and related method of use | |
| ZA201905677B (en) | Glycan-interacting compounds and methods of use | |
| IL257636A (en) | Anti-tigit antibodies and methods of use | |
| HUE068842T2 (hu) | Vegyületek és alkalmazási eljárásaik | |
| SG11201803213XA (en) | Glycan-interacting compounds and methods of use | |
| SG11201706583PA (en) | Anti-pvrig antibodies and methods of use | |
| IL313511A (en) | Compounds acting on glycans and methods of using them | |
| PL3089971T3 (pl) | Związki i sposoby ich zastosowania | |
| IL282482A (en) | Variants of protoxin-II and methods of use | |
| PL3313865T3 (pl) | Syntetyczne związki peptydowe i sposoby zastosowania | |
| GB201514760D0 (en) | Compounds and method of use | |
| PL3288379T3 (pl) | Kompozycje peptydowe i sposoby stosowania | |
| IL282508A (en) | Variants of protoxin-II and methods of use | |
| ZA201606450B (en) | Compounds and their methods of use | |
| IL247448A0 (en) | Peptides and methods of use | |
| GB201421888D0 (en) | Peptides derived from mysoin 19 and methods of use thereof | |
| GB201403697D0 (en) | Compounds and methods of use | |
| GB201504211D0 (en) | Use of peptides |